Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Hoiczyk M, Flasshove M, Hense J, Bojko P, Metz K, Moritz T, Seeber S, Nowrousian MR. Schütt P, et al. Among authors: buttkereit u. Eur J Haematol. 2005 Jan;74(1):40-6. doi: 10.1111/j.1600-0609.2004.00349.x. Eur J Haematol. 2005. PMID: 15613105 Clinical Trial.
Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Poser M, Müller S, Flasshove M, Moritz T, Seeber S, Nowrousian MR. Schütt P, et al. Among authors: buttkereit u. Ann Hematol. 2005 Sep;84(9):594-600. doi: 10.1007/s00277-005-1007-7. Epub 2005 Mar 3. Ann Hematol. 2005. PMID: 15744524 Clinical Trial.
In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.
Schütt P, Buttkereit U, Brandhorst D, Lindemann M, Schmiedl S, Grosse-Wilde H, Seeber S, Nowrousian MR, Opalka B, Moritz T. Schütt P, et al. Among authors: buttkereit u. Cancer Immunol Immunother. 2005 May;54(5):506-12. doi: 10.1007/s00262-004-0633-6. Epub 2004 Nov 20. Cancer Immunol Immunother. 2005. PMID: 15750834 Free PMC article.
Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.
Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, Poser M, Mueller S, Ebeling P, Welt A, Bradwell AR, Buttkereit U, Opalka B, Flasshove M, Moritz T, Seeber S. Nowrousian MR, et al. Among authors: buttkereit u. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8706-14. doi: 10.1158/1078-0432.CCR-05-0486. Clin Cancer Res. 2005. PMID: 16361557
Decreased Soluble Human Leukocyte Antigen E Levels in Patients After Allogeneic Hematopoietic Stem Cell Transplantation Are Associated With Severe Acute and Extended Chronic Graft-versus-Host Disease and Inferior Overall Survival.
Kordelas L, Schwich E, Lindemann M, Heinemann FM, Buttkereit U, Horn PA, Beelen DW, Rebmann V. Kordelas L, et al. Among authors: buttkereit u. Front Immunol. 2020 Jan 10;10:3027. doi: 10.3389/fimmu.2019.03027. eCollection 2019. Front Immunol. 2020. PMID: 31998310 Free PMC article.
Clinical Utility of Quantitative PCR for Chimerism and Engraftment Monitoring after Allogeneic Stem Cell Transplantation for Hematologic Malignancies.
Ahci M, Stempelmann K, Buttkereit U, Crivello P, Trilling M, Heinold A, Steckel NK, Koldehoff M, Horn PA, Beelen DW, Fleischhauer K. Ahci M, et al. Among authors: buttkereit u. Biol Blood Marrow Transplant. 2017 Oct;23(10):1658-1668. doi: 10.1016/j.bbmt.2017.05.031. Epub 2017 Jun 8. Biol Blood Marrow Transplant. 2017. PMID: 28603070 Free article.
12 results